Cephalon Oncology is going further to maximize therapeutic potential and extend patient benefits worldwide. In addition to our drug discovery program, which is bringing transforming impetus to the management of hematological malignancies, we market several products internationally, two of which are commercialized in the United States:

TREANDA^® (bendamustine HCl) for Injection

TREANDA for Injection is indicated for treatment of patients with:

• Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established
• Indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen

See full prescribing information. Click for more information about TREANDA.

TRISENOX^® (arsenic trioxide) injection

TRISENOX is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. www.TRISENOX.com

See full prescribing information including BOXED WARNINGS. Click for more information about TRISENOX.